NovaBay Pharmaceuticals, Inc. (NBY) CEO Interviewed on RedChip Money Report on Fox Business News  
3/18/2013 12:46:59 PM

EMERYVILLE, Calif., March 18, 2013 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with first-in-class compounds such as its proprietary Aganocides®, today announced that Dr. Ron Najafi, NovaBay's Chairman and Chief Executive Officer, was featured on the RedChip Money Report episode that aired on Fox Business on March 16, 2013. Dr. Najafi provided an overview of the Company's anti-infective programs and highlighted the Company's three Phase 2 trials currently underway, studying the Company's lead Aganocide auriclosene (NVC-422) in dermatology, ophthalmology, and urology. NovaBay's partnership with the world leading dermatology company, Galderma, SA., as well as its recently launched product for the treatment of chronic non-healing wounds, NeutroPhase®, were also highlighted.